RxDoctor Payments Data

Sara Reed

Family · Folsom, CANPI 1225207913

Payments from drug & device makers

$2,459in general payments, 2019–2025

Across 120 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$683
  • Takeda Pharmaceuticals U.S.A., Inc.$439
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$350
  • Otsuka America Pharmaceutical, Inc.$244
  • Johnson & Johnson$188
  • Lundbeck LLC$164
  • plus $391 from 10 others

What the payments were for

  • Food & beverage$2,459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,459 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$87,211
Medicare patients
170
Services billed
1,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl22$35,076
Invega SustennaPaliperidone Palmitate11$27,334
RexultiBrexpiprazole16$25,678
TrintellixVortioxetine Hydrobromide21$13,547
Aripiprazole138$13,522
BelsomraSuvorexant27$11,244
Bupropion XlBupropion Hcl155$3,788
Quetiapine Fumarate193$3,263
Olanzapine102$3,144
Buspirone Hcl231$3,081
Hydroxyzine Hcl83$2,660
Doxepin Hcl56$2,645
Adderall XrDextroamphetamine/Amphetamine12$2,521
Venlafaxine Hcl ErVenlafaxine Hcl136$2,361
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$2,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$683$35,07622 claims
Johnson & JohnsonInvega Sustenna$188$27,33411 claims
Otsuka America Pharmaceutical, Inc.Rexulti$244$25,67816 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$439$13,54721 claims
Almatica Pharma LLCSertraline Hcl$51$736112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Folsom

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →